2 Information about durvalumab

Marketing authorisation indication

2.1

Durvalumab (Imfinzi, AstraZeneca) is indicated as monotherapy for 'the treatment of adults with limited-stage small cell lung cancer (LS‑SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.'

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the summary of product characteristics for durvalumab.

Price

2.3

The list price is £592 for a 120-mg vial and £2,466 for a 500-mg vial (excluding VAT; BNF online accessed June 2025).

2.4

The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

For information, the Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.